| scholarly article | Q13442814 |
| P50 | author | Marc Espié | Q99591504 |
| Philippe Bertheau | Q115606211 | ||
| Louis-François Plassa | Q115606219 | ||
| Hugues de Thé | Q33103207 | ||
| Jacqueline Lehmann-Che | Q41608370 | ||
| Fabrice André | Q41743842 | ||
| P2093 | author name string | Elisabeth Turpin | |
| Michel Marty | |||
| Lajos Pusztai | |||
| W Fraser Symmans | |||
| Christos Sotiriou | |||
| Christine Desmedt | |||
| Martine Piccart | |||
| Chafika Mazouni | |||
| Sylvie Giacchetti | |||
| P2860 | cites work | High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors | Q42447874 |
| Identification of molecular apocrine breast tumours by microarray analysis. | Q42478400 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy | Q44146957 | ||
| Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? | Q44323220 | ||
| A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients | Q44443792 | ||
| p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes | Q46714384 | ||
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. | Q46966638 | ||
| Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. | Q52542729 | ||
| Cancer biology: Can less be more for p53? | Q59007923 | ||
| Achilles' heel of cancer? | Q59091650 | ||
| p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial | Q59567679 | ||
| Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients | Q71169983 | ||
| Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25 | Q73153238 | ||
| Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22 | Q73368640 | ||
| High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients | Q78200350 | ||
| Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer | Q80362521 | ||
| Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen | Q21092375 | ||
| In search of the tumour-suppressor functions of BRCA1 and BRCA2 | Q28748477 | ||
| Clinical implications of p53 mutations | Q33538157 | ||
| p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation | Q33733341 | ||
| Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer | Q33852049 | ||
| Disruption of p53 in human cancer cells alters the responses to therapeutic agents | Q33853609 | ||
| P63 and P73: P53 mimics, menaces and more | Q34185768 | ||
| A simple p53 functional assay for screening cell lines, blood, and tumors | Q34397902 | ||
| Assessing TP53 status in human tumours to evaluate clinical outcome | Q34570100 | ||
| HER-2 and topoisomerase II as predictors of response to chemotherapy | Q34747499 | ||
| Family feud in chemosensitvity: p73 and mutant p53. | Q35636547 | ||
| Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer | Q35901185 | ||
| Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis | Q36620640 | ||
| Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. | Q36642141 | ||
| TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes | Q36777326 | ||
| An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen | Q40313659 | ||
| Cancer therapy and p53. | Q40938367 | ||
| Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents | Q41228017 | ||
| High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. | Q42163493 | ||
| Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer | Q42163501 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 246-252 | |
| P577 | publication date | 2010-03-12 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers | |
| P478 | volume | 15 |
| Q52584340 | 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. |
| Q38206546 | Advances in the approach to novel drug clinical development for breast cancer |
| Q37895805 | CMF revisited in the 21st century |
| Q33739325 | Chemosensitivity and p53; new tricks by an old dog |
| Q40907746 | Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo |
| Q38715267 | Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway |
| Q42511112 | Distinct tumor protein p53 mutants in breast cancer subgroups |
| Q37933098 | Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers |
| Q33827045 | Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy |
| Q37650748 | Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. |
| Q47195056 | Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery |
| Q38087850 | Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers |
| Q34113899 | Oxazaphosphorines: new therapeutic strategies for an old class of drugs |
| Q42315543 | Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy |
| Q89727347 | TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines |
| Q38999130 | TP53 Mutations in Breast and Ovarian Cancer |
| Q41519051 | TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer |
| Q35043933 | TP53 status and response to treatment in breast cancers |
| Q34234217 | TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial |
| Q34576275 | TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy |
| Q36544248 | Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors |
| Q47567895 | Translational opportunities for broad-spectrum natural phytochemicals and targeted agent combinations in breast cancer |
| Q38647802 | Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification. |
| Q36061177 | Triple-negative breast cancer: are we making headway at least? |
| Q38659283 | p53 as an Effector or Inhibitor of Therapy Response |
| Q27851827 | p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. |
Search more.